Parkinson’s disease is a long-term (chronic) neurological condition that affects more than 10 million people worldwide. Currently there is no treatment for Parkinson’s Disease, only drugs that address symptoms.
Genuity Science's Parkinson's Disease clinicogenomic dataset covers a comprehensive discovery cohort. Detailed clinical and laboratory data help define disease subtype, severity, and rate of progression. Genomic data includes whole genome sequencing at a typical 30x depth along with other -omic and deep phenotypic data from several thousand participants.
Genuity Science partners with drug discovery teams in many disease areas to provide answers to their toughest research questions. Learn more about our approach below and see how deeper, richer datasets can accelerate your research program.
We start by combining population-scale high quality whole genome sequence data with detailed clinical phenotype data to help distinguish signal from noise for a given disease. Distilling candidate targets from initial hits requires several layers of analysis. These analysis phases work like a funnel to narrow down and genomically validate hits. Our experienced team of scientists works with you every step of the way with a goal of delivering candidate targets for your drug development program.
In this webinar, Genuity Science Principal Scientist Anthony Ryan, PhD discusses the importance and value of deep phenotyping when looking for genomic associations to disease.